Structural design and site-specific conjugation in bispecific ADCs

“...we know that the specificity of our antibodies and their controlled conjugation helps us target tumor tissue while avoiding engagement with healthy tissues...”

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Sarka Stehlikova, Director, Biologics Core Technologies, SOTIO, about the design of bispecific ADCs for addressing tumor heterogeneity. They discuss the importance of site-specific conjugation and DAR control, and how precise payload placement influences stability and safety in complex ADC architectures.

Please enter your email to access content Read now